TSLP and Eczematoid dermatitis: A small phase 2a clinical trial using class III topical corticosteroids plus tezepelumab, a TSLP monoclonal antibody that blocks the interaction of TSLP to its receptor complex, achieved a numerical but statistically non-significant reduction in eczema-severity scores over placebo at week 12, with more excellent week 16 responses (66).